Skip to main content
The AAOS has published their Clinical Practice Guideline for Management of Osteoarthritis of the Knee (Non-Arthroplasty)

Dr. John Cush RheumNow

2 weeks 5 days ago
The AAOS has published their Clinical Practice Guideline for Management of Osteoarthritis of the Knee (Non-Arthroplasty); updating 19 of the 29 evidence-based recommendations and focuses on nonsurgical treatmentss to provide pain and patient function. https://t.co/faLi0X840d https://t.co/8iZkNEFkRy
RA,hand,elderly,active
Rheumatoid arthritis (RA) imparts a significant disabilty and quality of life (QoL) limitations worsened by aging, but also by malnutrition.
exhaustion,depression
Lupus Frailty Index Predicts Organ Damage
  • MedPage Today
Patients with longstanding systemic lupus erythematosus (SLE) who were considered frail were more likely to accrue disease damage over time, a secondary analysis of data from a Chicago lupus cohort found.
Study of 380 nonintubated severe COVID-19 pneumonia patients showed that those with the highest tertiles of FERRITIN (13

Dr. John Cush RheumNow

2 weeks 5 days ago
Study of 380 nonintubated severe COVID-19 pneumonia patients showed that those with the highest tertiles of FERRITIN (1322-13 ,418) showed significant reduction in mortality (HR, 0.16; 0.06-0.45) if given methylprednisolone [120-240] mg https://t.co/Jr1aWlPpOk
Secukinumab (IL-17 inhibitors) can be safely used in HIV spondyloarthritis patients. https://t.co/hpCRJkR9w7

Dr. John Cush RheumNow

2 weeks 5 days ago
Secukinumab (IL-17 inhibitors) can be safely used in HIV spondyloarthritis patients. https://t.co/hpCRJkR9w7
EHR record study: prevalence of Psoriatic arthritis (#PsA) was increased w/ psoriasis severity. PsA prevalence=2.9 per 1

Dr. John Cush RheumNow

2 weeks 5 days ago
EHR record study: prevalence of Psoriatic arthritis (#PsA) was increased w/ psoriasis severity. PsA prevalence=2.9 per 100 PY; Based on severity - Mild 2.1/100PY; Moderate 9.9/100PY & severe PSO: PsA risk was 17.6/100PY https://t.co/hXeA773KN4 https://t.co/AUIYZiSq5k
Novel study of Pain Reprocessing Therapy;PRT in Chronic Back Pain. 151 pts w/ 10 yrs of LBP: 4 wk results - better w/ PR

Dr. John Cush RheumNow

2 weeks 6 days ago
Novel study of Pain Reprocessing Therapy;PRT in Chronic Back Pain. 151 pts w/ 10 yrs of LBP: 4 wk results - better w/ PRT (66%) (were pain-or nearly pain-free) vs PBO (20%) vs Usual care (10%), with gains maintained through 1-year follow-up https://t.co/lioI99GP80
NEJM Clinical Images: Sweets syndrome (Acute Febrile Neutrophilic Dermatosis) - 46F w/ raised painful lesions on extremi

Dr. John Cush RheumNow

2 weeks 6 days ago
NEJM Clinical Images: Sweets syndrome (Acute Febrile Neutrophilic Dermatosis) - 46F w/ raised painful lesions on extremities. https://t.co/up5PviNDeS)
knee2_0.JPG (keep)
The American Academy of Orthopaedic Surgeons has published their Clinical Practice Guideline for Management of Osteoarthritis of the Knee (Non-Arthroplasty); updating 19 of the 29 evidence-based recommendations and focuses on nonsurgical treatmentss to provide pain and patient function.
ICYMI:

New data from the CDC shows that obesity rates have risen in the USA during the pandemic, with 16 states having

Dr. John Cush RheumNow

2 weeks 6 days ago
ICYMI: New data from the CDC shows that obesity rates have risen in the USA during the pandemic, with 16 states having obesity rates of 35% or higher - that's four more than last year, adding Delaware, Iowa, Ohio and Texas to the list. https://t.co/9nFuea2BOV https://t.co/XmsXmFXhzv
POETYK PSO-1 and PSO-2 trial results seen at the EADV meeting, studying Tyk2 inhibitor, deucravacitinib vs PBO or apremi

Dr. John Cush RheumNow

2 weeks 6 days ago
POETYK PSO-1 and PSO-2 trial results seen at the EADV meeting, studying Tyk2 inhibitor, deucravacitinib vs PBO or apremilast in 666 & 1020 plaque psoriasis pts. Wk 16 PASI 75 higher in DEUC ((59%, 54%) vs Otezla (35%, 40%) vs PBO(13%,9%) https://t.co/qok68Kbb6J
ASBMR meeting presented results of the ASTEROID trial in osteogenesis imperfecta; Setrusumab, investigational Mab inhibi

Dr. John Cush RheumNow

2 weeks 6 days ago
ASBMR meeting presented results of the ASTEROID trial in osteogenesis imperfecta; Setrusumab, investigational Mab inhibitor of sclerostin, failed to improve radial trabecular BMD (primary endpt), but did improve lumbar/hip/femoral BMD https://t.co/xSDIiffjb7
RA patients had a higher 30-day rehospitalization than OA after TKR (OR 1.11) and THR (OR, 1.39). While infections, post

Dr. John Cush RheumNow

2 weeks 6 days ago
RA patients had a higher 30-day rehospitalization than OA after TKR (OR 1.11) and THR (OR, 1.39). While infections, postoperative complications, cardiac did not differ, RA TKR had less VTE, but RA THR had higher VTE risk (OR, 2.41) https://t.co/QlOWngcEnJ
Stills disease and SpA? 8 pts (5 AOSD, 3 systemic JIA) who met Stills and ASAS criteria, 7/8 developed SpA a meant of 6.

Dr. John Cush RheumNow

3 weeks ago
Stills disease and SpA? 8 pts (5 AOSD, 3 systemic JIA) who met Stills and ASAS criteria, 7/8 developed SpA a meant of 6.2 yrs after Stills Dz. SpA types included 2 peripheral, 3 axial SpA, 4 PsA & 1 SAPHO. Amongst Stills pts 7-10% developed SpA https://t.co/RfeUxE7N7S
ICYMI:

Download today! “Jack of All Subspecialties”—find wherever you get your podcasts.

https://t.co/UvQRiLOWsr

Dr. John Cush RheumNow

3 weeks ago
ICYMI: Download today! “Jack of All Subspecialties”—find wherever you get your podcasts. https://t.co/UvQRiLOWsr #RheumNow https://t.co/IiFSBhWCcH
×